



PEGSITACIANINE FOR THE SURGICAL DETECTION OF HEAD AND NECK CANCER

| PURPOSE | INCLUSION | DESIGN |
|---|--|---|
| <p>To investigate whether Pegsitacianine a fluorescent nanoparticle can image head and neck cancer and unknown primary head and neck cancer during surgery or biopsy.</p> | <ol style="list-style-type: none"> Adults \geq 18 years of age Patients with stage 1-4 Head and Neck Squamous Cell Carcinoma (HNSCC) undergoing surgical excision | <ol style="list-style-type: none"> Phase 2 Clinical trial of Pegsitacianine, which is not yet FDA approved, for fluorescent imaging of primary tumors and metastatic lymph nodes in patients with head and neck cancer Efficacy of Pegsitacianine for detecting unknown primary head and neck cancers |

RESEARCH COORDINATOR

Phone: 214-648-6840

Email: OTOREsearch@UTSouthwestern.edu

LOCATION

UT Southwestern Medical Center
 Baran D. Sumer, M.D., F.A.C.S.
 Professor of Otolaryngology- Head and Neck Surgery
 2001 Inwood Road, 7th Floor
 Dallas, Texas, 75235

For more details refer to
<https://clinicaltrials.gov/>
 Identifier: **NCT05576974**

#37055276.1
 IRB Approved at the Study Level
 May 03, 2023

For more information, contact Research team at OTOREsearch@utsouthwestern.edu